[
  {
    "ts": "2025-12-15T12:07:15+00:00",
    "headline": "Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera",
    "summary": "Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma therapy Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron’s push to extend its oncology footprint and expand into genetic medicines,...",
    "url": "https://finance.yahoo.com/news/regeneron-regn-5-4-myeloma-120715099.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2295baf8-b9d9-3de1-9e2c-519273dd6859",
      "content": {
        "id": "2295baf8-b9d9-3de1-9e2c-519273dd6859",
        "contentType": "STORY",
        "title": "Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera",
        "description": "",
        "summary": "Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma therapy Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron’s push to extend its oncology footprint and expand into genetic medicines,...",
        "pubDate": "2025-12-15T12:07:15Z",
        "displayTime": "2025-12-15T12:07:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-5-4-myeloma-120715099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-5-4-myeloma-120715099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]